IL287385A - Use of an anti-cd19 antibody to treat autoimmune disease - Google Patents

Use of an anti-cd19 antibody to treat autoimmune disease

Info

Publication number
IL287385A
IL287385A IL287385A IL28738521A IL287385A IL 287385 A IL287385 A IL 287385A IL 287385 A IL287385 A IL 287385A IL 28738521 A IL28738521 A IL 28738521A IL 287385 A IL287385 A IL 287385A
Authority
IL
Israel
Prior art keywords
antibody
autoimmune disease
treat autoimmune
treat
disease
Prior art date
Application number
IL287385A
Other languages
English (en)
Hebrew (he)
Original Assignee
Viela Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viela Bio Inc filed Critical Viela Bio Inc
Publication of IL287385A publication Critical patent/IL287385A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL287385A 2019-04-24 2021-10-19 Use of an anti-cd19 antibody to treat autoimmune disease IL287385A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962838093P 2019-04-24 2019-04-24
US201962843096P 2019-05-03 2019-05-03
US201962858495P 2019-06-07 2019-06-07
PCT/US2020/029613 WO2020219743A2 (en) 2019-04-24 2020-04-23 Use of an anti-cd19 antibody to treat autoimmune disease

Publications (1)

Publication Number Publication Date
IL287385A true IL287385A (en) 2021-12-01

Family

ID=72940915

Family Applications (1)

Application Number Title Priority Date Filing Date
IL287385A IL287385A (en) 2019-04-24 2021-10-19 Use of an anti-cd19 antibody to treat autoimmune disease

Country Status (12)

Country Link
US (1) US20220204617A1 (https=)
EP (1) EP3959241A4 (https=)
JP (2) JP7779738B2 (https=)
KR (1) KR20220004113A (https=)
CN (1) CN113939532A (https=)
AU (1) AU2020263418A1 (https=)
BR (1) BR112021020924A2 (https=)
CA (1) CA3136487A1 (https=)
IL (1) IL287385A (https=)
MX (1) MX2021012870A (https=)
SG (1) SG11202111429UA (https=)
WO (1) WO2020219743A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3809260A1 (de) * 2019-10-18 2021-04-21 Siemens Healthcare GmbH System und verfahren zur administration von bildgebenden geräten
JP2023534916A (ja) * 2020-06-30 2023-08-15 ビエラ バイオ インコーポレイテッド 視神経脊髄炎スペクトラム障害を治療する方法
JP2023549075A (ja) * 2020-10-29 2023-11-22 ビエラ バイオ インコーポレイテッド 自己免疫疾患を治療するための抗cd19抗体の使用
IL308296A (en) * 2021-05-07 2024-01-01 Viela Bio Inc Use of anti-CD19 antibody to treat myasthenia gravis
KR20250044695A (ko) 2022-07-27 2025-04-01 비엘라 바이오, 인크. 이네빌리주맙 및 지속적인 b-세포 고갈을 위한 이의 사용 방법
WO2024155810A1 (en) * 2023-01-20 2024-07-25 Viela Bio, Inc. Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101456728B1 (ko) * 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-cd19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
SI2066349T1 (sl) * 2006-09-08 2012-08-31 Medimmune Llc Humanizirana anti-cd19 protitelesa in njihova uporaba v zdravljenju tumorjev, transplantacijah in avtoimunih boleznih
MX2011009312A (es) * 2009-03-06 2012-02-29 Medimmune Llc Formulaciones de anticuerpos humanizados anti-cd19.
CN104640560A (zh) * 2012-03-12 2015-05-20 米迪缪尼有限公司 用抗-cd19抗体治疗多发性硬化症
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease

Also Published As

Publication number Publication date
MX2021012870A (es) 2022-01-18
WO2020219743A2 (en) 2020-10-29
US20220204617A1 (en) 2022-06-30
EP3959241A4 (en) 2023-01-25
JP2022529743A (ja) 2022-06-23
EP3959241A2 (en) 2022-03-02
SG11202111429UA (en) 2021-11-29
BR112021020924A2 (pt) 2022-04-19
JP7779738B2 (ja) 2025-12-03
JP2025157413A (ja) 2025-10-15
CA3136487A1 (en) 2020-10-29
CN113939532A (zh) 2022-01-14
KR20220004113A (ko) 2022-01-11
AU2020263418A1 (en) 2021-11-11
WO2020219743A3 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
IL287385A (en) Use of an anti-cd19 antibody to treat autoimmune disease
IL284280A (en) Improved antibody-oligonucleotide conjugate
EP3857879A4 (en) COMBINED INTER-INTRA PREDICTION SIMPLIFICATION
CL2018000728A1 (es) Anticuerpos anti-cd19 humano humanizados y métodos de utilización
IL256079A (en) Humanized and affinity matured antibodies to fcrh5 and methods of use
IL279894A (en) Antibodies binding to ilt4
IL311039A (en) Anti-cd3 antibodies
JOP20170004B1 (ar) الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
LT3383916T (lt) Antikūnai prieš cd73 ir jų panaudojimo būdai
PL3468997T3 (pl) Leczenie chorób związanych z lgG4 przeciwciałami anty-CD19 wiążącymi się krzyżowo z CD32b
IL287039A (en) Cd19 antibodies and methods of using the same
IL283473A (en) Rnai constructs for inhibiting pnpla3 expression
IL284367A (en) Monoclonal antibodies that bind specifically to human trbv9
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
EA201790719A1 (ru) Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
EA201591974A1 (ru) Антитела человека, связывающиеся с g-белком rsv
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
IL285401A (en) Anti-clec2d antibodies and methods of use thereof
EP3713955A4 (en) ANTI-IFNAR1 ANTIBODIES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
UA123202C2 (uk) Антитіло до тау-білка і його застосування
PT3280440T (pt) Anticorpos anti-c1s humanizados e métodos de utilização destes
IL254951B (en) Humanized influenza monoclonal antibodies and methods of use thereof
IL283136A (en) Antibodies to mucin-16 and methods of use thereof
IL280278A (en) Fcrn antibody compositions